EI
MDGL icon

EAM Investors’s Madrigal Pharmaceuticals MDGL Stock Holding History

EAM Investors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,837
Closed -$7.48M – 341
2025
Q4 		$7.48M Buy
12,837
+1,993
+18% +$1.02M 0.83% 6
2025
Q3 		$4.89M Buy
+10,844
New +$4.05M 0.56% 66
2025
Q2 		– Sell
-14,557
Closed -$4.82M – 307
2025
Q1 		$4.82M Buy
+14,557
New +$4.78M 0.83% 14
2023
Q2 		– Sell
-6,205
Closed -$1.5M – 318
2023
Q1 		$1.5M Sell
6,205
-993
-14% -$271K 0.3% 172
2022
Q4 		$2.09M Buy
+7,198
New +$704K 0.43% 87
2018
Q4 		– Sell
-12,699
Closed -$2.72M – 294
2018
Q3 		$2.72M Sell
12,699
-7,807
-38% -$1.96M 0.4% 123
2018
Q2 		$5.74M Sell
20,506
-7,438
-27% -$1.31M 0.9% 2
2018
Q1 		$3.26M Sell
27,944
-16,945
-38% -$2.09M 0.54% 56
2017
Q4 		$4.12M Buy
+44,889
New +$2.56M 0.74% 9

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM Investors's MDGL Position: Q1 2026 in Review

EAM Investors sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 12,837 shares — an estimated $7.48M sold.

EAM Investors first reported a position in MDGL in Q4 2017 and held it in 9 quarters. The position peaked at $7.48M in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • EAM Investors reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 12,837 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $7.48M.
  • EAM Investors first reported a position in Madrigal Pharmaceuticals in Q4 2017 and held it in 9 quarters.
  • EAM Investors's Madrigal Pharmaceuticals position peaked at $7.48M in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.